Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Opthea Ltd (OPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.63 -0.05    -6.67%
26/04 - Closed. Currency in AUD ( Disclaimer )
  • Volume: 672,529
  • Bid/Ask: 0.62 / 0.66
  • Day's Range: 0.62 - 0.67
Type:  Equity
Market:  Australia
ISIN:  AU000000OPT2 
Opthea 0.63 -0.05 -6.67%

Opthea Company Profile

 
Read the Opthea Ltd company profile to learn more about the business and the management team. View Opthea Ltd facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Contact Information

Address 650 Chapel Street Suite 0403
Level 4 South Yarra, 3141
Australia
Phone 61 3 9826 0399
Fax 61 3 9824 0083

Top Executives

Name Age Since Title
Jeremy Max Levin 68 2020 Chairperson
Lawrence B. Gozlan 44 2020 Independent Non-Executive Director
Tim Jackson - - Member of Clinical Advisory Board
Julia A. Haller 68 2021 Independent Non-Executive Director
Jason Scott Slakter 65 - Member of Clinical Advisory Board
Charles C. Wykoff - - Member of Clinical Advisory Board
Megan Baldwin 49 2014 Founder, Chief Innovation Officer & Executive Director
Quinton C. Oswald 73 2022 Independence Non-Executive Director
Susan C. Orr 61 2022 Independent Non-Executive Director
Sujal A. Shah 51 2024 Non-Executive Director
Anshul Thakral 46 2023 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OPT Price Commentary

Write your thoughts about Opthea Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email